.jpg)
Opthea scraps wet AMD program after eye drug loses out to Lucentis in latest phase 3 fail
Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to can the entire wet age-related macular degeneration program.
Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to can the entire wet age-related macular degeneration program.
